ArticleFrontiers in pharmacology2025
Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety of herbal medicine decoction for facial palsy: Coarsened exact matching analysis of the national health insurance database.Integrative medicine research · 2026Article
- Hepatotoxicity Assessment of Anshenbunao Syrup by Multi-Component Quantification In Vivo/In Vitro and Cell Biological Evaluations.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug-induced liver injury (DILI) is a significant health concern caused by exposure to pharmaceuticals, over-the-counter medications, herbal remedies, and dietary supplements. The contribution of prescribed herbal medicines to DILI risk remains unclear. This study aimed to evaluate the hepatotoxicity risk associated with traditional Korean medicines (TKMs) using nationwide health insurance claims data. Methods: A tailored cohort of patients diagnosed with DILI (ICD-10 code: K71) between January 2011 and December 2019 was obtained from the Health Insurance Review and Assessment Service. After applying inclusion and exclusion criteria, 672,411 patients were identified. Using a self-controlled case study (SCCS) design, exposures were defined as hospital/clinic visits or medication prescriptions within a 90-day window. Analyses were conducted across three groups: outpatients, inpatients, and patients with liver disease. Relative incidences of DILI were calculated for different exposure scenarios. Results: Outpatients showed the highest relative incidences of DILI 3-15 days after visiting Western hospitals/clinics or being prescribed commercial drugs, with risk estimates of 1.55 (95% confidence interval [CI]: 1.55-1.56) and 2.44 (95% CI: 2.43-2.44), respectively. These risks gradually declined to baseline levels (1.0). All other groups exhibited similar patterns. In contrast, DILI risks associated with TKM hospital/clinic visits and herbal medicine prescriptions were minimal, with relative risks of 1.01 (95% CI: 1.00-1.01) and 0.99 (95% CI: 0.99-0.99), respectively. However, a mildly elevated risk was observed in patients with liver disease. Conclusion: This nationwide cohort study demonstrates that herbal medicines prescribed by TKM practitioners have minimal impact on DILI risk. Patients with pre-existing liver disease exhibit increased susceptibility to DILI. Differentiating between unregulated herbal products and those prescribed in medical institutions is essential for accurate assessment of hepatotoxicity risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.